Department of Gynaecological Oncology Publications

Publications 2023

  1. Bjerre Trent P, Falk RS, Staff AC, Jorde D, Eriksson AG (2023)
    Translation and cross-cultural adaptation of the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire
    Int J Gynecol Cancer, 33 (2), 231-235
    DOI 10.1136/ijgc-2022-003979, PubMed 36600491
  2. Karamouza E, Glasspool RM, Kelly C, Lewsley LA, Carty K, Kristensen GB, Ethier JL, Kagimura T, Yanaihara N, Cecere SC, You B, Boere IA, Pujade-Lauraine E, Ray-Coquard I, Proust-Lima C, Paoletti X (2023)
    CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
    Cancers (Basel), 15 (6)
    DOI 10.3390/cancers15061823, PubMed 36980708
  3. Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S (2023)
    Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
    Clin Cancer Res (in press)
    DOI 10.1158/1078-0432.CCR-22-2032, PubMed 36595569

Publications 2022

  1. Baranovicova E, Racay P, Zubor P, Smolar M, Kudelova E, Halasova E, Dvorska D, Dankova Z (2022)
    Circulating metabolites in the early stage of breast cancer were not related to cancer stage or subtypes but associated with ki67 level. Promising statistical discrimination from controls
    Mol Cell Probes, 66, 101862
    DOI 10.1016/j.mcp.2022.101862, PubMed 36162596
  2. Brunetti M, Panagopoulos I, Vitelli V, Andersen K, Hveem TS, Davidson B, Eriksson AGZ, Trent PKB, Heim S, Micci F (2022)
    Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile
    Cancers (Basel), 14 (14)
    DOI 10.3390/cancers14143536, PubMed 35884597
  3. Davidson B, Elstrand MB (2022)
    Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions
    Cytopathology, 33 (4), 479-492
    DOI 10.1111/cyt.13126, PubMed 35398934
  4. Daviu C, Blaakaer J, Eriksson AGZ, Herrstedt J, Vandborg MP, Rasmussen AMO, Fuglsang K (2022)
    Nonepithelial ovarian cancer - the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO)
    Acta Oncol, 61 (8), 939-945
    DOI 10.1080/0284186X.2022.2088249, PubMed 35762031
  5. Gatius S, Velasco A, Varela M, Cuatrecasas M, Jares P, Setaffy L, Bonhomme B, Santon A, Lindemann K, Croce S, Davidson B, Lax S, Palacios J, Matias-Guiu X (2022)
    Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
    Virchows Arch, 480 (5), 1031-1039
    DOI 10.1007/s00428-022-03291-x, PubMed 35124717
  6. Kurnit KC, Nobre SP, Fellman BM, Iglesias DA, Lindemann K, Jhingran A, Eriksson AGZ, Ataseven B, Glaser GE, Mueller JJ, Westin SN, Soliman PT (2022)
    Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study
    Gynecol Oncol, 167 (3), 452-457
    DOI 10.1016/j.ygyno.2022.09.025, PubMed 36243601
  7. Madland K, Bjorge L, Småstuen MC, Dørum A, Vistad I (2022)
    Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?
    Int J Gynecol Cancer (in press)
    DOI 10.1136/ijgc-2022-003361, PubMed 35680138
  8. Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Høgdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH (2022)
    Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
    Cancer, 128 (16), 3080-3089
    DOI 10.1002/cncr.34350, PubMed 35714310
  9. Nilsen A, Hillestad T, Skingen VE, Aarnes EK, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H (2022)
    miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
    Mol Oncol, 16 (6), 1402-1419
    DOI 10.1002/1878-0261.13184, PubMed 35064630
  10. O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A (2022)
    Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
    Gynecol Oncol, 166 (1), 36-43
    DOI 10.1016/j.ygyno.2022.04.012, PubMed 35550709
  11. Paulsen T, Liland H, Myklebust TÅ, Lindemann K (2022)
    Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study
    Int J Gynecol Cancer, 32 (2), 181-188
    DOI 10.1136/ijgc-2021-002898, PubMed 34987096
  12. Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner ML, Hartkopf AD, Baumann K, Hasenburg A, Hanker LC, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch C, Burges A, Lück HJ, Emons G, Meier W et al. (2022)
    Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
    J Clin Oncol, 41 (4), 893-902
    DOI 10.1200/JCO.22.01010, PubMed 36332161
  13. Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E (2022)
    Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
    Gynecol Oncol, 164 (3), 498-504
    DOI 10.1016/j.ygyno.2021.12.025, PubMed 35063276
  14. Siegenthaler F, Lindemann K, Epstein E, Rau TT, Nastic D, Ghaderi M, Rydberg F, Mueller MD, Carlson J, Imboden S (2022)
    Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification
    Gynecol Oncol, 165 (2), 230-238
    DOI 10.1016/j.ygyno.2022.02.024, PubMed 35277281
  15. Skipar K, Hompland T, Lund KV, Løndalen A, Malinen E, Kristensen GB, Lindemann K, Nakken ES, Bruheim K, Lyng H (2022)
    Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
    Radiother Oncol, 176, 17-24
    DOI 10.1016/j.radonc.2022.09.002, PubMed 36113778
  16. Utne I, Stokke K, Ritchie C, Løyland B, Grov EK, Rasmussen HL, Lindemann K, Paul SM, Torstveit AH, Miaskowski C (2022)
    Changes in Subjective Measures of Cognitive Function in Older Adults From the Initiation Through 12 Months After the Receipt of Chemotherapy
    Cancer Nurs (in press)
    DOI 10.1097/NCC.0000000000001140, PubMed 35781267

Publications 2021

  1. Areklett EW, Fagereng E, Bruheim K, Andersson S, Lindemann K (2021)
    Self-reported cognitive impairment in cervical cancer survivors: A cross-sectional study
    Psychooncology, 31 (2), 298-305
    DOI 10.1002/pon.5818, PubMed 34516040
  2. Bhandoria GP, Nair N, Jones SEF, Eriksson AG, Hsu HC, Noll F, Ahmed W, International Gynecological Cancer Society (2021)
    International Gynaecological Cancer Society (IGCS) 2020 Annual Global Meeting: Twitter activity analysis
    Int J Gynecol Cancer, 31 (11), 1453-1458
    DOI 10.1136/ijgc-2021-002781, PubMed 34489352
  3. Davidson B, Kleinberg L, Børresen IM, Slettevoll F, Fangberget A, Hindosh D, Zahl Eriksson AG, Bjerkehagen B (2021)
    Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis
    Virchows Arch, 479 (2), 419-424
    DOI 10.1007/s00428-021-03057-x, PubMed 33595736
  4. Eriksson AGZ, Davidson B, Bjerre Trent P, Eyjólfsdóttir B, Dahl GF, Wang Y, Staff AC (2021)
    Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma
    J Clin Med, 10 (14)
    DOI 10.3390/jcm10143094, PubMed 34300260
  5. Eriksson AGZ, Mueller JJ (2021)
    Advances in management of nonendometrioid endometrial carcinoma, with an emphasis on the sentinel lymph node technique
    Curr Opin Oncol, 33 (5), 457-463
    DOI 10.1097/CCO.0000000000000777, PubMed 34264897
  6. Gansmo LB, Sofiyeva N, Bjørnslett M, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
    Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
    Sci Rep, 11 (1), 23463
    DOI 10.1038/s41598-021-02820-z, PubMed 34873230
  7. Helwa R, Gansmo LB, Bjørnslett M, Halle MK, Werner HMJ, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
    Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer
    Biomarkers, 26 (4), 302-308
    DOI 10.1080/1354750X.2021.1891291, PubMed 33645339
  8. Kargo AS, Jensen PT, Lindemann K, Hjollund NHI, Lund B, Haee M, Möller S, Hansen DG, Dahl Steffensen K (2021)
    The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness
    Acta Oncol, 60 (4), 434-443
    DOI 10.1080/0284186X.2021.1891281, PubMed 33651647
  9. Kargo AS, Jensen PT, Lindemann K, Hjøllund NH, Liposits GI, Raaschou-Jensen N, Knudsen BM, Möller S, Hansen DG, Steffensen KD (2021)
    Association of patient-reported outcomes and ovarian cancer recurrence
    Int J Gynecol Cancer, 31 (9), 1248-1259
    DOI 10.1136/ijgc-2021-002550, PubMed 34489355
  10. Kasius JC, Pijnenborg JMA, Lindemann K, Forsse D, van Zwol J, Kristensen GB, Krakstad C, Werner HMJ, Amant F (2021)
    Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification
    Cancers (Basel), 13 (22)
    DOI 10.3390/cancers13225848, PubMed 34831000
  11. Kolkova Z, Holubekova V, Grendar M, Nachajova M, Zubor P, Pribulova T, Loderer D, Zigo I, Biringer K, Hornakova A (2021)
    Association of Circulating miRNA Expression with Preeclampsia, Its Onset, and Severity
    Diagnostics (Basel), 11 (3)
    DOI 10.3390/diagnostics11030476, PubMed 33800458
  12. Lindemann K (2021)
    Medical treatment of primary and recurrent cervical cancer
    Int. J. Gynecol. Cancer, 31 1, 20
  13. Lindemann K (2021)
    Medical treatment of primary and recurrent cervical cancer
    Int. J. Gynecol. Cancer, 31 2, 18
  14. Lindemann K, Smogeli E, Småstuen MC, Bruheim K, Trovik J, Nordberg T, Kristensen GB, Werner HMJ, Nakken E (2021)
    Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer
    Cancers (Basel), 13 (6)
    DOI 10.3390/cancers13061367, PubMed 33803531
  15. Oonk MHM, Slomovitz B, Baldwin PJW, van Doorn HC, van der Velden J, de Hullu JA, Gaarenstroom KN, Slangen BFM, Vergote I, Brännström M, van Dorst EBL, van Driel WJ, Hermans RH, Nunns D, Widschwendter M, Nugent D, Holland CM, Sharma A, DiSilvestro PA, Mannel R, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB et al. (2021)
    Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
    J Clin Oncol, 39 (32), 3623-3632
    DOI 10.1200/JCO.21.00006, PubMed 34432481
  16. Seland M, Skrede K, Lindemann K, Skaali T, Blomhoff R, Bruheim K, Wisløff T, Thorsen L (2021)
    Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer
    Acta Obstet Gynecol Scand, 101 (3), 313-322
    DOI 10.1111/aogs.14310, PubMed 34964982
  17. Seppälä TT, Dominguez-Valentin M, Crosbie EJ, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel W et al. (2021)
    Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report
    Eur J Cancer, 148, 124-133
    DOI 10.1016/j.ejca.2021.02.022, PubMed 33743481
  18. Sert BM, Kristensen GB, Kleppe A, Dørum A (2021)
    Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience
    Gynecol Oncol, 162 (2), 284-291
    DOI 10.1016/j.ygyno.2021.05.028, PubMed 34083029
  19. Skorstad M, de Rooij BH, Jeppesen MM, Bergholdt SH, Ezendam NPM, Bohlin T, Jensen PT, Lindemann K, van de Poll L, Vistad I (2021)
    Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study
    Int J Gynecol Cancer, 31 (8), 1106-1115
    DOI 10.1136/ijgc-2020-002377, PubMed 33858949
  20. Utne I, Løyland B, Grov EK, Rasmussen HL, Torstveit AH, Paul SM, Ritchie C, Lindemann K, Vistad I, Rodríguez-Aranda C, Miaskowski C (2021)
    Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy
    Nurs Open, 9 (2), 1040-1051
    DOI 10.1002/nop2.1141, PubMed 34878233
  21. van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Forsse D, Witteveen PO, Galaal K, van Ginkel A, Bignotti E, Weinberger V, Sweegers S, Kroep JR, Cabrera S, Snijders MPLM, Inda MA, Eriksson AGZ, European Network for Individualized Treatment in Endometrial Cancer, Krakstad C, Romano A et al. (2021)
    Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
    Am J Obstet Gynecol, 225 (4), 407.e1-407.e16
    DOI 10.1016/j.ajog.2021.05.007, PubMed 34019887
  22. Vistad I, Skorstad M, Demmelmaier I, Småstuen MC, Lindemann K, Wisløff T, van de Poll-Franse LV, Berntsen S (2021)
    Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking
    BMJ Open, 11 (7), e050930
    DOI 10.1136/bmjopen-2021-050930, PubMed 34253678

Publications 2020

  1. Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H (2020)
    Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
    EBioMedicine, 57, 102841
    DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139
  2. Harter P, Pautier P, Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Petru E, Heitz F, Sehouli J, Degregorio N, Wimberger P, Burges A, Cron N, Ledermann J, Lorusso D, Paoletti X, Marme F (2020)
    Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
    Int J Gynecol Cancer, 30 (12), 1997-2001
    DOI 10.1136/ijgc-2020-001572, PubMed 32606097
  3. Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, Lyng H (2020)
    MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
    Cancer Res, 80 (18), 3993-4003
    DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004
  4. Holubekova V, Kolkova Z, Grendar M, Brany D, Dvorska D, Stastny I, Jagelkova M, Zelinova K, Samec M, Liskova A, Laucekova Z, Kudela E, Bobrovska M, Kalman M, Zubor P, Dankova Z (2020)
    Pathway Analysis of Selected Circulating miRNAs in Plasma of Breast Cancer Patients: A Preliminary Study
    Int J Mol Sci, 21 (19)
    DOI 10.3390/ijms21197288, PubMed 33023154
  5. Kargo AS, Coulter A, Lindemann K, Jensen PT, Hjøllund NH, Mosgaard BJ, Steffensen KD (2020)
    Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol
    Int J Gynecol Cancer, 30 (9), 1444-1449
    DOI 10.1136/ijgc-2020-001528, PubMed 32586892
  6. Kleppe A, Albregtsen F, Trovik J, Kristensen GB, Danielsen HE (2020)
    Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas
    Cancers (Basel), 12 (12)
    DOI 10.3390/cancers12123838, PubMed 33352679
  7. Koklesova L, Liskova A, Samec M, Qaradakhi T, Zulli A, Smejkal K, Kajo K, Jakubikova J, Behzadi P, Pec M, Zubor P, Biringer K, Kwon TK, Büsselberg D, Sarria GR, Giordano FA, Golubnitschaja O, Kubatka P (2020)
    Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine
    EPMA J, 11 (2), 261-287
    DOI 10.1007/s13167-020-00210-5, PubMed 32547652
  8. La Russa M, Zapardiel I, Zalewski K, Laky R, Dursun P, Sukhin V, Lindquist D, Lindemann K (2020)
    Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members
    BMJ Support Palliat Care (in press)
    DOI 10.1136/bmjspcare-2020-002233, PubMed 32958506
  9. Lanner M, Nikolova T, Gutic B, Nikolova N, Pletnev A, Selcuk I, Vlachos DE, Razumova Z, Bizzarri N, Theofanakis C, Lepka P, Kahramanoglu I, Han S, Nasser S, Molnar S, Hudry D, Montero-Macías R, de Lange N, Macuks R, Hasanov MF, Karimbayli R, Gagua I, Andrade C, Pardal C, Dotlic J et al. (2020)
    Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists
    Int J Gynecol Cancer, 31 (4), 575-584
    DOI 10.1136/ijgc-2020-002176, PubMed 33361458
  10. Lindemann K (2020)
    Systematic treatment of primary and recurrent cervical cancer
    Int. J. Gynecol. Cancer, 30 1, 15
  11. Lindemann K, Martinsson L, Kaasa S, Lindquist D (2020)
    Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
    Acta Oncol, 59 (6), 636-643
    DOI 10.1080/0284186X.2020.1744717, PubMed 32238040
  12. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2020)
    DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
    Radiat Oncol, 15 (1), 79
    DOI 10.1186/s13014-020-01526-2, PubMed 32293487
  13. Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA (2020)
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
    Gynecol Oncol, 159 (2), 442-448
    DOI 10.1016/j.ygyno.2020.09.006, PubMed 32981695
  14. Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C et al. (2020)
    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
    J Clin Oncol, 38 (32), 3753-3762
    DOI 10.1200/JCO.20.01164, PubMed 32822286
  15. Norell CH, Butler J, Farrell R, Altman A, Bentley J, Cabasag CJ, Cohen PA, Fegan S, Fung-Kee-Fung M, Gourley C, Hacker NF, Hanna L, Høgdall CK, Kristensen G, Kwon J, McNally O, Nelson G, Nordin A, O'Donnell D, Schnack T, Sykes PH, Zotow E, Harrison S (2020)
    Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care
    Int J Gynecol Cancer, 30 (11), 1748-1756
    DOI 10.1136/ijgc-2020-001403, PubMed 32784203
  16. Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, Kristensen G, Ottevanger PB, Aravantinos G, Miller A, Boere IA, Fruscio R, Reyners AKL, Pujade-Lauraine E, Harkin A, Pignata S, Kagimura T, Welch S, Paul J, Karamouza E, Glasspool RM, Gynecologic Cancer InterGroup (GCIG) Meta-analysis Committee (2020)
    Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
    JAMA Netw Open, 3 (1), e1918939
    DOI 10.1001/jamanetworkopen.2019.18939, PubMed 31922558
  17. Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Gonzalez Martin A, Jhingran A, Pareja R (2020)
    COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers
    Int J Gynecol Cancer, 30 (5), 561-563
    DOI 10.1136/ijgc-2020-001419, PubMed 32221023
  18. Ramirez PT, Pareja R, Eriksson AGZ, Frumovitz M (2020)
    International Gynecologic Cancer Society 2019 meeting summary
    Int J Gynecol Cancer, 30 (2), 167-173
    DOI 10.1136/ijgc-2019-001146, PubMed 32029483
  19. Rolfsen ALD, Dahl AA, Pripp AH, Dørum A (2020)
    Base rate of ovarian cancer on algorithms in patients with a pelvic mass
    Int J Gynecol Cancer, 30 (11), 1775-1779
    DOI 10.1136/ijgc-2020-001416, PubMed 32699016
  20. Salminen L, Nadeem N, Rolfsen AL, Dørum A, Laajala TD, Grènman S, Hietanen S, Heinosalo T, Perheentupa A, Poutanen M, Bolstad N, Carpén O, Lamminmäki U, Pettersson K, Gidwani K, Hynninen J, Huhtinen K (2020)
    Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
    J Appl Lab Med, 5 (2), 263-272
    DOI 10.1093/jalm/jfz012, PubMed 32445385
  21. Samec M, Liskova A, Koklesova L, Samuel SM, Murin R, Zubor P, Bujnak J, Kwon TK, Büsselberg D, Prosecky R, Caprnda M, Rodrigo L, Ciccocioppo R, Kruzliak P, Kubatka P (2020)
    The role of plant-derived natural substances as immunomodulatory agents in carcinogenesis
    J Cancer Res Clin Oncol, 146 (12), 3137-3154
    DOI 10.1007/s00432-020-03424-2, PubMed 33063131
  22. Samec M, Liskova A, Koklesova L, Samuel SM, Zhai K, Buhrmann C, Varghese E, Abotaleb M, Qaradakhi T, Zulli A, Kello M, Mojzis J, Zubor P, Kwon TK, Shakibaei M, Büsselberg D, Sarria GR, Golubnitschaja O, Kubatka P (2020)
    Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
    EPMA J, 11 (3), 377-398
    DOI 10.1007/s13167-020-00217-y, PubMed 32843908
  23. Stastny I, Zubor P, Kajo K, Kubatka P, Golubnitschaja O, Dankova Z (2020)
    Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer
    Clin Breast Cancer, 20 (6), e711-e722
    DOI 10.1016/j.clbc.2020.05.009, PubMed 32792225
  24. Vistad I, Lindemann K, Bentzen AG, Dahl AA, Steen R, Kiserud C (2020)
    Preferences for follow up in long-term survivors after cervical cancer
    Acta Obstet Gynecol Scand, 99 (9), 1253-1259
    DOI 10.1111/aogs.13855, PubMed 32232835
  25. Zubor P, Dankova Z, Kolkova Z, Holubekova V, Brany D, Mersakova S, Samec M, Liskova A, Koklesova L, Kubatka P, Bujnak J, Kajo K, Mlyncek M, Giordano FA, Golubnitschaja O (2020)
    Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare
    Cancers (Basel), 12 (5)
    DOI 10.3390/cancers12051292, PubMed 32443784
  26. Zubor P, Wang Y, Liskova A, Samec M, Koklesova L, Dankova Z, Dørum A, Kajo K, Dvorska D, Lucansky V, Malicherova B, Kasubova I, Bujnak J, Mlyncek M, Dussan CA, Kubatka P, Büsselberg D, Golubnitschaja O (2020)
    Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology
    Int J Mol Sci, 21 (21)
    DOI 10.3390/ijms21217988, PubMed 33121141

Publications 2019

  1. Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW (2019)
    Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
    Clin Cancer Res, 25 (7), 2155-2165
    DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134
  2. Eriksson AG, Fallaas Dahl G, Nesbakken AJ, Lund KV, Amant F (2019)
    Endometrial cancer during pregnancy: management strategies
    Int J Gynecol Cancer, 29 (7), 1221-1224
    DOI 10.1136/ijgc-2019-000756, PubMed 31434687
  3. Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA (2019)
    Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
    Gynecol Oncol, 152 (3), 560-567
    DOI 10.1016/j.ygyno.2018.12.009, PubMed 30638768
  4. Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H (2019)
    Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
    Neoplasia, 21 (4), 353-362
    DOI 10.1016/j.neo.2019.01.002, PubMed 30856376
  5. Lindemann K, Zalewski K, Halaska MJ (2019)
    Summary of landmark papers published between August 2018 and May 2019
    Int. J. Gynecol. Cancer, 29 1, 1-5
    DOI 10.1136/ijgc-2019-000738
  6. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2019)
    Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model
    Acta Oncol, 58 (6), 828-837
    DOI 10.1080/0284186X.2019.1580386, PubMed 30810443
  7. Nilsen A, Jonsson M, Aarnes EK, Kristensen GB, Lyng H (2019)
    Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers
    Transl Oncol, 12 (3), 576-584
    DOI 10.1016/j.tranon.2018.12.010, PubMed 30660934
  8. Piovano E, Ferrero A, Zola P, Marth C, Mirza MR, Lindemann K (2019)
    Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
    Int J Gynecol Cancer, 29 (1), 181-187
    DOI 10.1136/ijgc-2018-000021, PubMed 30640702
  9. Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L (2019)
    PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
    Cochrane Database Syst Rev, 10 (10), CD012160
    DOI 10.1002/14651858.CD012160.pub2, PubMed 31588998

Publications 2018

  1. González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ, ICON7 investigators (2018)
    Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
    Gynecol Oncol, 152 (1), 53-60
    DOI 10.1016/j.ygyno.2018.08.036, PubMed 30449719
  2. Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE (2018)
    Chromatin organisation and cancer prognosis: a pan-cancer study
    Lancet Oncol, 19 (3), 356-369
    DOI 10.1016/S1470-2045(17)30899-9, PubMed 29402700
  3. Lindemann K (2018)
    Medical treatment of primary and recurrent cervical cancer
    Int. J. Gynecol. Cancer, 28 4, 29
  4. Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D, For ANZGOG and HCRN Collaborative Groups (2018)
    Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
    Cancer Chemother Pharmacol, 83 (1), 97-105
    DOI 10.1007/s00280-018-3706-5, PubMed 30368585
  5. Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A (2018)
    Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
    Gynecol Oncol, 150 (2), 239-246
    DOI 10.1016/j.ygyno.2018.05.020, PubMed 29807697
  6. Lindemann K, Zalewski K, Halaska MJ, Lindquist D (2018)
    PREFACE
    Int. J. Gynecol. Cancer, 28 4, 2
  7. Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S (2018)
    White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
    Ann Intern Med, 168 (5), 326-334
    DOI 10.7326/M17-0101, PubMed 29335712
  8. Nielsen B, Kleppe A, Hveem TS, Pradhan M, Syvertsen RA, Nesheim JA, Kristensen GB, Trovik J, Kerr DJ, Albregtsen F, Danielsen HE (2018)
    Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
    J Natl Cancer Inst, 110 (12), 1400-1408
    DOI 10.1093/jnci/djy063, PubMed 29684152
  9. Noer MC, Leandersson P, Paulsen T, Rosthøj S, Antonsen SL, Borgfeldt C, Høgdall C (2018)
    Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study
    Acta Oncol, 57 (8), 1100-1108
    DOI 10.1080/0284186X.2018.1440085, PubMed 29451070
  10. Simonsen TG, Lund KV, Hompland T, Kristensen GB, Rofstad EK (2018)
    DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
    Int J Radiat Oncol Biol Phys, 102 (4), 1193-1201
    DOI 10.1016/j.ijrobp.2018.04.035, PubMed 29859790
  11. Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K (2018)
    Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
    Int J Gynecol Cancer, 28 (9), 1789-1795
    DOI 10.1097/IGC.0000000000001356, PubMed 30365455
  12. Solheim O, Skalleberg J, Warncke T, Ørstavik K, Tropé C, Fosså SD (2018)
    Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
    Acta Obstet Gynecol Scand, 98 (2), 240-249
    DOI 10.1111/aogs.13477, PubMed 30289161
  13. Szczesny W, Langseth H, Myklebust TÅ, Kaern J, Tropé C, Paulsen T (2018)
    Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
    Acta Obstet Gynecol Scand, 97 (8), 956-965
    DOI 10.1111/aogs.13361, PubMed 29790149

Publications 2017

  1. Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
    MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
    Oncotarget, 8 (37), 61800-61809
    DOI 10.18632/oncotarget.18694, PubMed 28977905
  2. Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-Jensen T, Katz B (2017)
    Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
    Virchows Arch, 471 (3), 355-362
    DOI 10.1007/s00428-017-2172-5, PubMed 28643014
  3. Eriksson AG, Beavis A, Soslow RA, Zhou Q, Abu-Rustum NR, Gardner GJ, Zivanovic O, Long Roche K, Sonoda Y, Leitao MM, Jewell EL (2017)
    A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer
    Int J Gynecol Cancer, 27 (4), 743-747
    DOI 10.1097/IGC.0000000000000959, PubMed 28375931
  4. Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2017)
    MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
    BMC Cancer, 17 (1), 97
    DOI 10.1186/s12885-017-3094-y, PubMed 28158999
  5. Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R (2017)
    TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
    Virchows Arch, 470 (6), 665-678
    DOI 10.1007/s00428-017-2127-x, PubMed 28432432
  6. Hardell E, Josefson S, Ghaderi M, Skeie-Jensen T, Westbom-Fremer S, Cheek EH, Bell D, Selling J, Schoolmeester JK, Måsbäck A, Davidson B, Carlson JW (2017)
    Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
    Am J Surg Pathol, 41 (9), 1231-1237
    DOI 10.1097/PAS.0000000000000894, PubMed 28622181
  7. Johansen N, Liavaag AH, Iversen OE, Dørum A, Braaten T, Michelsen TM (2017)
    Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
    Acta Obstet Gynecol Scand, 96 (5), 547-555
    DOI 10.1111/aogs.13120, PubMed 28236297
  8. Landskron J, Kraggerud SM, Wik E, Dørum A, Bjørnslett M, Melum E, Helland Ø, Bjørge L, Lothe RA, Salvesen HB, Taskén K (2017)
    C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
    PLoS One, 12 (7), e0182030
    DOI 10.1371/journal.pone.0182030, PubMed 28759630
  9. Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G (2017)
    Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
    Br J Cancer, 116 (4), 455-463
    DOI 10.1038/bjc.2016.435, PubMed 28118323
  10. Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A (2017)
    Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
    Int J Gynecol Cancer, 27 (6), 1274-1282
    DOI 10.1097/IGC.0000000000000981, PubMed 28498237
  11. Lindemann K, Kok PS, Stockler M, Sykes P, Brand A (2017)
    Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
    Int J Gynecol Cancer, 27 (5), 1046-1050
    DOI 10.1097/IGC.0000000000000982, PubMed 28525497
  12. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2017)
    Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
    Acta Oncol, 56 (5), 675-681
    DOI 10.1080/0284186X.2017.1294762, PubMed 28447564
  13. Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB, Tropé CG, Lie AK, Vistad I (2017)
    Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
    Gynecol Oncol, 145 (3), 543-548
    DOI 10.1016/j.ygyno.2017.03.008, PubMed 28356187
  14. Minig L, Heitz F, Cibula D, Bakkum-Gamez JN, Germanova A, Dowdy SC, Kalogera E, Zapardiel I, Lindemann K, Harter P, Scambia G, Petrillo M, Zorrero C, Zanagnolo V, Rebollo JMC, du Bois A, Fotopoulou C (2017)
    Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
    Ann Surg Oncol, 24 (9), 2720-2726
    DOI 10.1245/s10434-017-5919-y, PubMed 28608122
  15. Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA, RARECARENet Working Group (2017)
    Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
    Eur J Surg Oncol, 45 (1), 67-74
    DOI 10.1016/j.ejso.2017.09.025, PubMed 29108961
  16. Skalleberg J, Solheim O, Fosså SD, Småstuen MC, Osnes T, Gundersen POM, Bunne M (2017)
    Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer
    Gynecol Oncol, 145 (1), 148-153
    DOI 10.1016/j.ygyno.2017.02.006, PubMed 28202195
  17. Solheim O, Førsund M, Tropé CG, Kraggerud SM, Nesland JM, Davidson B (2017)
    Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
    APMIS, 125 (9), 781-786
    DOI 10.1111/apm.12715, PubMed 28585395
  18. Steen R, Dahl AA, Hess SL, Kiserud CE (2017)
    A study of chronic fatigue in Norwegian cervical cancer survivors
    Gynecol Oncol, 146 (3), 630-635
    DOI 10.1016/j.ygyno.2017.05.028, PubMed 28552254
  19. Vistad I, Bjørge L, Solheim O, Fiane B, Sachse K, Tjugum J, Skrøppa S, Bentzen AG, Stokstad T, Iversen GA, Salvesen HB, Kristensen GB, Dørum A (2017)
    A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
    Acta Obstet Gynecol Scand, 96 (10), 1162-1169
    DOI 10.1111/aogs.13199, PubMed 28795770
  20. Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
    The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
    Neuro Oncol, 19 (7), 976-985
    DOI 10.1093/neuonc/now272, PubMed 28040713
  21. Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
    Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
    Acta Oncol, 56 (10), 1302-1309
    DOI 10.1080/0284186X.2017.1330554, PubMed 28548875
  22. Zalewski K, Lindemann K, Halaska MJ, Zapardiel I, Laky R, Chereau E, Lindquist D, Polterauer S, Sukhin V, Dursun P (2017)
    A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
    Int J Gynecol Cancer, 27 (3), 620-626
    DOI 10.1097/IGC.0000000000000917, PubMed 28187096

Publications 2016

  1. Bjørge T, Skare GB, Bjørge L, Tropé A, Lönnberg S (2016)
    Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia
    Obstet Gynecol, 128 (6), 1265-1273
    DOI 10.1097/AOG.0000000000001777, PubMed 27824756
  2. Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM (2016)
    Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
    Am J Clin Pathol, 145 (4), 449-58
    DOI 10.1093/ajcp/aqw030, PubMed 27149024
  3. Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H (2016)
    Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
    Clin Cancer Res, 22 (16), 4067-76
    DOI 10.1158/1078-0432.CCR-15-2322, PubMed 27012812
  4. Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H (2016)
    Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
    PLoS One, 11 (5), e0156259
    DOI 10.1371/journal.pone.0156259, PubMed 27244197
  5. Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S (2016)
    The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
    Tumour Biol, 37 (8), 10697-702
    DOI 10.1007/s13277-016-4940-2, PubMed 26867771
  6. Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A (2016)
    Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
    Gynecol Oncol, 142 (3), 458-64
    DOI 10.1016/j.ygyno.2016.06.023, PubMed 27444035
  7. Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A (2016)
    Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
    Gynecol Oncol, 140 (3), 457-62
    DOI 10.1016/j.ygyno.2016.01.022, PubMed 26807488
  8. Horwitz V, Davidson B, Stern D, Tropé CG, Tavor Re'em T, Reich R (2016)
    Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
    PLoS One, 11 (9), e0162502
    DOI 10.1371/journal.pone.0162502, PubMed 27622508
  9. Lindemann K (2016)
    Medical treatment of primary or recurrent cervical cancer
    Int. J. Gynecol. Cancer, 26 1, 42-43
  10. Lindemann K, Halaska MJ, Zalewski K (2016)
    Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
    Int. J. Gynecol. Cancer, 26 1, 5-8
  11. Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E (2016)
    Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
    Ann Oncol, 27 (8), 1505-10
    DOI 10.1093/annonc/mdw238, PubMed 27407100
  12. Lindemann K, Zalewski K, Halaska MJ, LiFE Team (2016)
    Preface
    Int. J. Gynecol. Cancer, 26 1, 2
  13. Lindemann K, Zalewski K, Halaska MJ, Lindquist D, The LiFE Team (2016)
    Life - Literature for ENYGO
    Int. J. Gynecol. Cancer, 26 4, 2-73
  14. Lönnberg S, Andreassen T, Engesæter B, Lilleng R, Kleven C, Skare A, Johansson K, Fredheim CS, Tropé A (2016)
    Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention
    BMJ Open, 6 (11), e013728
    DOI 10.1136/bmjopen-2016-013728, PubMed 28186949
  15. Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K (2016)
    Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
    Oncologist, 21 (6), 745-54
    DOI 10.1634/theoncologist.2015-0239, PubMed 27009938
  16. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J et al. (2016)
    Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    N Engl J Med, 375 (22), 2154-2164
    DOI 10.1056/NEJMoa1611310, PubMed 27717299
  17. Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
    MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
    Hum Pathol, 54, 74-81
    DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471
  18. Sert BM, Boggess JF, Ahmad S, Jackson AL, Stavitzski NM, Dahl AA, Holloway RW (2016)
    Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer
    Eur J Surg Oncol, 42 (4), 513-22
    DOI 10.1016/j.ejso.2015.12.014, PubMed 26843445
  19. Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
    L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
    BMC Cancer, 16, 596
    DOI 10.1186/s12885-016-2631-4, PubMed 27488577
  20. Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E, AURELIA Investigators (2016)
    Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
    Gynecol Oncol, 144 (1), 65-71
    DOI 10.1016/j.ygyno.2016.11.006, PubMed 27871723
  21. Szczesny W, Vistad I, Kaern J, Nakling J, Tropé C, Paulsen T (2016)
    Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
    Eur J Gynaecol Oncol, 37 (3), 305-11
    DOI 10.12892/ejgo3007.2016, PubMed 27352555
  22. Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ (2016)
    Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
    Oncotarget, 7 (11), 12267-85
    DOI 10.18632/oncotarget.7860, PubMed 26943585
  23. Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E (2016)
    Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
    Ann Oncol, 27 (9), 1733-9
    DOI 10.1093/annonc/mdw236, PubMed 27287207
  24. Zalewski K, Lindemann K, Halaska MJ (2016)
    Medical treatment of primary ovarian cancer
    Int. J. Gynecol. Cancer, 26 1, 9-11
  25. Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC (2016)
    Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
    Br J Cancer, 115 (2), 228-35
    DOI 10.1038/bjc.2016.194, PubMed 27351218

Publications 2015

  1. Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EM, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M (2015)
    Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
    PLoS One, 10 (12), e0143178
    DOI 10.1371/journal.pone.0143178, PubMed 26629914
  2. Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A (2015)
    Psychological distress related to BRCA testing in ovarian cancer patients
    Fam Cancer, 14 (4), 495-504
    DOI 10.1007/s10689-015-9811-2, PubMed 25980896
  3. Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R (2015)
    HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
    Hum Pathol, 48, 95-101
    DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230
  4. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO et al. (2015)
    Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
    Lancet Oncol, 17 (1), 78-89
    DOI 10.1016/S1470-2045(15)00366-6, PubMed 26590673
  5. Katz B, Tropé CG, Reich R, Davidson B (2015)
    MicroRNAs in Ovarian Cancer
    Hum Pathol, 46 (9), 1245-56
    DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350
  6. Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H (2015)
    Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
    Epigenetics, 10 (10), 970-80
    DOI 10.1080/15592294.2015.1085140, PubMed 26291246
  7. Lindemann K, Cvancarova M, Eskild A (2015)
    Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
    Gynecol Oncol, 139 (3), 476-80
    DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365
  8. Murbraech K, Solheim O, Aulie HM, Fossa SD, Aakhus S (2015)
    The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer
    ESC Heart Fail, 2 (3), 142-149
    DOI 10.1002/ehf2.12048, PubMed 28834675
  9. Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B (2015)
    Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
    Gynecol Oncol, 139 (1), 30-9
    DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338
  10. Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B (2015)
    CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
    Mol Cancer, 14, 44
    DOI 10.1186/s12943-015-0317-1, PubMed 25889687
  11. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ, ICON7 trial investigators (2015)
    Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
    Lancet Oncol, 16 (8), 928-36
    DOI 10.1016/S1470-2045(15)00086-8, PubMed 26115797
  12. Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J (2015)
    Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
    Eur J Cancer, 51 (7), 825-32
    DOI 10.1016/j.ejca.2015.01.008, PubMed 25771433
  13. Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S et al. (2015)
    HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
    Genome Med, 7, 108
    DOI 10.1186/s13073-015-0233-4, PubMed 26497652
  14. Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2015)
    Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study)
    Eur J Epidemiol, 31 (1), 95-8
    DOI 10.1007/s10654-015-0033-6, PubMed 25903163

Publications 2014

  1. Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B (2014)
    Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma
    Int J Gynecol Cancer, 24 (9 Suppl 3), S67-72
    DOI 10.1097/IGC.0000000000000205, PubMed 25033257
  2. Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP (2014)
    The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
    Hum Pathol, 46 (1), 1-8
    DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994
  3. Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE (2014)
    BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
    Virchows Arch, 464 (6), 701-7
    DOI 10.1007/s00428-014-1577-7, PubMed 24756216
  4. Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK (2014)
    VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
    Hum Pathol, 45 (7), 1520-8
    DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803
  5. Davidson B, Tropé CG (2014)
    Ovarian cancer: diagnostic, biological and prognostic aspects
    Womens Health (Lond), 10 (5), 519-33
    DOI 10.2217/whe.14.37, PubMed 25335543
  6. Davidson B, Tropé CG, Reich R (2014)
    The clinical and diagnostic role of microRNAs in ovarian carcinoma
    Gynecol Oncol, 133 (3), 640-6
    DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546
  7. Davidson B, Trope CG, Reich R (2014)
    The role of the tumor stroma in ovarian cancer
    Front Oncol, 4, 104
    DOI 10.3389/fonc.2014.00104, PubMed 24860785
  8. Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK (2014)
    Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
    Radiother Oncol, 113 (1), 132-8
    DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501
  9. Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2014)
    CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
    PLoS One, 9 (11), e112209
    DOI 10.1371/journal.pone.0112209, PubMed 25380303
  10. Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B (2014)
    Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
    BMC Cancer, 14, 68
    DOI 10.1186/1471-2407-14-68, PubMed 24498853
  11. Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S (2014)
    Genomic profile of ovarian carcinomas
    BMC Cancer, 14, 315
    DOI 10.1186/1471-2407-14-315, PubMed 24886194
  12. Micci F, Panagopoulos I, Thorsen J, Davidson B, Tropé CG, Heim S (2014)
    Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
    PLoS Biol, 12 (2), e1001784
    DOI 10.1371/journal.pbio.1001784, PubMed 24504521
  13. Nielsen B, Hveem TS, Kildal W, Abeler VM, Kristensen GB, Albregtsen F, Danielsen HE (2014)
    Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas
    Cytometry A, 87 (4), 315-25
    DOI 10.1002/cyto.a.22601, PubMed 25483227
  14. Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
    Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
    Gynecol Oncol, 135 (1), 118-24
    DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290
  15. Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
    Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
    Genes Chromosomes Cancer, 53 (7), 558-67
    DOI 10.1002/gcc.22166, PubMed 24634323
  16. Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD (2014)
    Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010)
    Eur J Cancer, 50 (11), 1942-50
    DOI 10.1016/j.ejca.2014.03.288, PubMed 24857045
  17. Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD (2014)
    Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
    Gynecol Oncol, 136 (2), 224-9
    DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159
  18. Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B (2014)
    APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
    Am J Clin Pathol, 142 (1), 51-7
    DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085
  19. Vaksman O, Tropé C, Davidson B, Reich R (2014)
    Exosome-derived miRNAs and ovarian carcinoma progression
    Carcinogenesis, 35 (9), 2113-20
    DOI 10.1093/carcin/bgu130, PubMed 24925027
  20. Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B (2014)
    Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
    BMC Cancer, 14, 80
    DOI 10.1186/1471-2407-14-80, PubMed 24512620
  21. Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G (2014)
    A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
    BMC Cancer, 14, 937
    DOI 10.1186/1471-2407-14-937, PubMed 25494701

Publications 2013

  1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2013)
    Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
    Radiother Oncol, 107 (1), 117-22
    DOI 10.1016/j.radonc.2012.11.007, PubMed 23333024
  2. Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
    High levels of genomic aberrations in serous ovarian cancers are associated with better survival
    PLoS One, 8 (1), e54356
    DOI 10.1371/journal.pone.0054356, PubMed 23372714
  3. Davidson B, Abeler VM, Førsund M, Holth A, Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih IeM, Wang TL (2013)
    Gene expression signatures of primary and metastatic uterine leiomyosarcoma
    Hum Pathol, 45 (4), 691-700
    DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798
  4. Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG (2013)
    Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
    Hum Pathol, 44 (11), 2449-60
    DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953
  5. Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I, European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group (2013)
    Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
    Gynecol Oncol, 131 (2), 437-44
    DOI 10.1016/j.ygyno.2013.08.014, PubMed 23994107
  6. Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, Kristensen GB, Steenbergen RD, Lyng H (2013)
    Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
    J Pathol, 230 (1), 59-69
    DOI 10.1002/path.4168, PubMed 23335387
  7. Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K (2013)
    Long-term outcomes after pelvic radiation for early-stage endometrial cancer
    J Clin Oncol, 31 (31), 3951-6
    DOI 10.1200/JCO.2013.48.8023, PubMed 24019546
  8. Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD (2013)
    Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
    Gynecol Oncol, 131 (2), 330-5
    DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518
  9. Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B (2013)
    HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
    Gynecol Oncol, 129 (2), 358-63
    DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671
  10. Vaksman O, Davidson B, Tropé C, Reich R (2013)
    Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
    Hum Pathol, 44 (12), 2677-83
    DOI 10.1016/j.humpath.2013.07.009, PubMed 24060004
  11. Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF (2013)
    Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
    Hum Pathol, 44 (9), 1859-66
    DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974

Publications 2012

  1. Bjørnslett M, Knappskog S, Lønning PE, Dørum A (2012)
    Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
    BMC Cancer, 12, 454
    DOI 10.1186/1471-2407-12-454, PubMed 23039163
  2. Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
    Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
    Virchows Arch, 460 (2), 193-202
    DOI 10.1007/s00428-011-1191-x, PubMed 22249560
  3. Davidson B, Abeler VM, Hellesylt E, Holth A, Shih IeM, Skeie-Jensen T, Chen L, Yang Y, Wang TL (2012)
    Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
    Gynecol Oncol, 128 (2), 349-55
    DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314
  4. Davidson B, Holth A, Nguyen MT, Tropé CG, Wu C (2012)
    Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
    Gynecol Oncol, 128 (2), 364-70
    DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104
  5. Elgaaen BV, Olstad OK, Sandvik L, Odegaard E, Sauer T, Staff AC, Gautvik KM (2012)
    ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival
    PLoS One, 7 (9), e46317
    DOI 10.1371/journal.pone.0046317, PubMed 23029477
  6. Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG (2012)
    Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
    Acta Obstet Gynecol Scand, 91 (3), 308-17
    DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605
  7. Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J (2012)
    Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation
    Ann Surg Oncol, 20 (4), 1348-54
    DOI 10.1245/s10434-012-2673-z, PubMed 23054114
  8. Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM (2012)
    Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
    Clin Cancer Res, 18 (11), 3197-206
    DOI 10.1158/1078-0432.CCR-12-0056, PubMed 22492981
  9. Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuåsen RG, Sundfør K, Kristensen GB, Holm R, Malinen E, Lyng H (2012)
    Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
    Cancer Res, 72 (20), 5285-95
    DOI 10.1158/0008-5472.CAN-12-1085, PubMed 22890239
  10. Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B (2012)
    HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
    Virchows Arch, 460 (5), 505-13
    DOI 10.1007/s00428-012-1228-9, PubMed 22476403
  11. Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA (2012)
    Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
    Cancer Chemother Pharmacol, 69 (5), 1307-14
    DOI 10.1007/s00280-012-1835-9, PubMed 22302409
  12. Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B (2012)
    MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
    Gynecol Oncol, 126 (3), 460-5
    DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154
  13. Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B (2012)
    Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
    Hum Pathol, 44 (5), 777-85
    DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921
  14. Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E (2012)
    Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
    Br J Cancer, 106 (11), 1728-34
    DOI 10.1038/bjc.2012.158, PubMed 22531637
  15. Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E, Norwegian Breast Cancer Group trial NBCG VI, Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE (2012)
    MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
    PLoS One, 7 (4), e36263
    DOI 10.1371/journal.pone.0036263, PubMed 22558411
  16. Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M (2012)
    A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
    Ann Oncol, 24 (4), 937-43
    DOI 10.1093/annonc/mds538, PubMed 23104722
  17. Liang D, Ma Y, Liu J, Trope CG, Holm R, Nesland JM, Suo Z (2012)
    The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells
    BMC Cancer, 12, 201
    DOI 10.1186/1471-2407-12-201, PubMed 22642602
  18. Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB (2012)
    First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
    Ann Oncol, 23 (10), 2613-2619
    DOI 10.1093/annonc/mds060, PubMed 22539562
  19. Michelsen TM, Dørum A, Cvancarova M, Liavaag AH, Dahl AA (2012)
    Association between hysterectomy with ovarian preservation and cardiovascular disease in a Norwegian population-based sample
    Gynecol Obstet Invest, 75 (1), 61-7
    DOI 10.1159/000345072, PubMed 23220872
  20. Nielsen B, Albregtsen F, Kildal W, Abeler VM, Kristensen GB, Danielsen HE (2012)
    The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer
    Anal Cell Pathol (Amst), 35 (4), 305-14
    DOI 10.3233/ACP-2012-0065, PubMed 22596183
  21. Pradhan M, Davidson B, Abeler VM, Danielsen HE, Tropé CG, Kristensen GB, Risberg BÅ (2012)
    DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
    Virchows Arch, 461 (3), 291-8
    DOI 10.1007/s00428-012-1275-2, PubMed 22824999
  22. Tropé CG, Abeler VM, Kristensen GB (2012)
    Diagnosis and treatment of sarcoma of the uterus. A review
    Acta Oncol, 51 (6), 694-705
    DOI 10.3109/0284186X.2012.689111, PubMed 22793037
  23. Tropé CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H (2012)
    Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Eur J Cancer, 48 (14), 2146-54
    DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201
  24. Tropé CG, Kaern J, Davidson B (2012)
    Borderline ovarian tumours
    Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
    DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906
  25. Vaksman O, Hetland TE, Trope' CG, Reich R, Davidson B (2012)
    Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
    Hum Pathol, 43 (11), 2062-9
    DOI 10.1016/j.humpath.2012.02.016, PubMed 22647351
  26. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP (2012)
    Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
    Br J Cancer, 107 (4), 588-91
    DOI 10.1038/bjc.2012.307, PubMed 22836511
  27. Weiss I, Trope CG, Reich R, Davidson B (2012)
    Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure
    Int J Mol Sci, 13 (10), 12925-38
    DOI 10.3390/ijms131012925, PubMed 23202930

Publications 2011

  1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2011)
    Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
    Int J Radiat Oncol Biol Phys, 82 (3), e485-92
    DOI 10.1016/j.ijrobp.2011.05.050, PubMed 22014954
  2. Bock AJ, Dong HP, Tropé CG, Staff AC, Risberg B, Davidson B (2011)
    Nucleoside transporters are widely expressed in ovarian carcinoma effusions
    Cancer Chemother Pharmacol, 69 (2), 467-75
    DOI 10.1007/s00280-011-1716-7, PubMed 21822668
  3. Bock AJ, Nymoen DA, Brenne K, Kærn J, Davidson B (2011)
    SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
    Hum Pathol, 43 (5), 669-74
    DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113
  4. Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B (2011)
    Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
    Tumour Biol, 32 (3), 589-96
    DOI 10.1007/s13277-011-0157-6, PubMed 21350924
  5. Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B (2011)
    Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
    Hum Pathol, 43 (4), 496-505
    DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111
  6. Dahl AA, Gudbergsson SB, Dørum A, Fosså SD, Liavaag AH, Sørebø Ø (2011)
    "The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
    Qual Life Res, 21 (8), 1459-70
    DOI 10.1007/s11136-011-0053-y, PubMed 22045155
  7. Davidson B, Holth A, Moripen L, Trope' CG, Shih IeM (2011)
    Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
    Hum Pathol, 42 (7), 991-7
    DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424
  8. Dong HP, Ree Rosnes AK, Bock AJ, Holth A, Flørenes VA, Trope' CG, Risberg B, Davidson B (2011)
    Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
    Cytopathology, 22 (6), 373-82
    DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542
  9. Elstrand MB, Stavnes HT, Tropé CG, Davidson B (2011)
    Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
    Hum Pathol, 43 (4), 529-35
    DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883
  10. Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM (2011)
    Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions
    Mol Pharm, 8 (6), 2080-8
    DOI 10.1021/mp200240a, PubMed 21761824
  11. Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Piek JM, Manchanda R, Grimm C, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Steffensen KD, Gristsenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Tsolakidis D, Novak Z et al. (2011)
    Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists
    Int J Gynecol Cancer, 21 (8), 1500-6
    DOI 10.1097/IGC.0b013e3182202d17, PubMed 21720256
  12. Halle C, Lando M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
    Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
    Radiother Oncol, 101 (1), 152-7
    DOI 10.1016/j.radonc.2011.05.052, PubMed 21680035
  13. Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
    Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
    Clin Cancer Res, 17 (16), 5501-12
    DOI 10.1158/1078-0432.CCR-11-0297, PubMed 21737508
  14. Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J (2011)
    Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
    Hum Pathol, 42 (7), 1019-26
    DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408
  15. Kildal W, Micci F, Risberg B, Abeler VM, Kristensen GB, Heim S, Danielsen HE (2011)
    Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization
    Mol Oncol, 6 (1), 98-107
    DOI 10.1016/j.molonc.2011.10.002, PubMed 22062770
  16. Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC (2011)
    Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
    Cancer, 118 (6), 1543-53
    DOI 10.1002/cncr.26449, PubMed 22009736
  17. Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
    The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
    Cancer Cell, 19 (2), 273-82
    DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605
  18. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, Gynecologic Cancer Intergroup (2011)
    Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
    Ann Oncol, 22 (11), 2417-2423
    DOI 10.1093/annonc/mdr001, PubMed 21402619
  19. Oksefjell H, Sandstad B, Tropé C (2011)
    The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome
    Eur J Gynaecol Oncol, 32 (4), 369-76
    PubMed 21941955
  20. Paulsen T, Kærn J, Tropé C (2011)
    Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
    Gynecol Oncol, 122 (1), 83-8
    DOI 10.1016/j.ygyno.2011.02.038, PubMed 21435701
  21. Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ (2011)
    Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
    Ann Oncol, 23 (5), 1178-1184
    DOI 10.1093/annonc/mdr368, PubMed 21965471
  22. Sert MB, Abeler V (2011)
    Robot-assisted laparoscopic radical hysterectomy: comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital
    Gynecol Oncol, 121 (3), 600-4
    DOI 10.1016/j.ygyno.2011.02.002, PubMed 21353294
  23. Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P (2011)
    A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
    Ann Surg Oncol, 19 (2), 597-604
    DOI 10.1245/s10434-011-1873-2, PubMed 21732142
  24. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R (2011)
    miRNA profiling along tumour progression in ovarian carcinoma
    J Cell Mol Med, 15 (7), 1593-602
    DOI 10.1111/j.1582-4934.2010.01148.x, PubMed 20716115
  25. Vergote I, Tropé CG, Amant F, Ehlen T, Reed NS, Casado A (2011)
    Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer
    J Clin Oncol, 29 (31), 4076-8
    DOI 10.1200/JCO.2011.36.9785, PubMed 21931032
  26. Vistad I, Cvancarova M, Kristensen GB, Fosså SD (2011)
    A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer
    J Cancer Surviv, 5 (2), 208-16
    DOI 10.1007/s11764-011-0172-z, PubMed 21259075
  27. Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS (2011)
    Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
    Br J Cancer, 105 (7), 890-6
    DOI 10.1038/bjc.2011.328, PubMed 21878937

Publications 2010

  1. Bock AJ, Stavnes HT, Kempf T, Tropè CG, Berner A, Davidson B, Staff AC (2010)
    Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
    Int J Gynecol Cancer, 20 (9), 1448-55
    DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029
  2. Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B (2010)
    Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
    Hum Pathol, 41 (6), 794-804
    DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512
  3. Davidson B, Reich R, Trope CG, Wang TL, Shih IeM (2010)
    New determinates of disease progression and outcome in metastatic ovarian carcinoma
    Histol Histopathol, 25 (12), 1591-609
    DOI 10.14670/HH-25.1591, PubMed 20886439
  4. du Bois A, Herrstedt J, Hardy-Bessard AC, Muller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J (2010)
    Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer
    J. Clin. Oncol., 28 (27), 4162-4169
    DOI 10.1200/JCO.2009.27.4696
  5. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, Staff AC, Sauer T, Gautvik KM (2010)
    POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas
    PLoS One, 5 (11), e13837
    DOI 10.1371/journal.pone.0013837, PubMed 21079801
  6. Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R (2010)
    Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
    Clin Exp Metastasis, 27 (3), 161-72
    DOI 10.1007/s10585-010-9315-2, PubMed 20213325
  7. Hovland S, Arbyn M, Lie AK, Ryd W, Borge B, Berle EJ, Skomedal H, Kadima TM, Kyembwa L, Billay EM, Mukwege D, Chirimwami RB, Mvula TM, Snijders PJ, Meijer CJ, Karlsen F (2010)
    A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
    Br J Cancer, 102 (6), 957-65
    DOI 10.1038/sj.bjc.6605594, PubMed 20197765
  8. Micci F, Haugom L, Ahlquist T, Andersen HK, Abeler VM, Davidson B, Trope CG, Lothe RA, Heim S (2010)
    Genomic aberrations in borderline ovarian tumors
    J Transl Med, 8, 21
    DOI 10.1186/1479-5876-8-21, PubMed 20184781
  9. Micci F, Skotheim RI, Haugom L, Weimer J, Eibak AM, Abeler VM, Trope CG, Arnold N, Lothe RA, Heim S (2010)
    Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes
    Genes Chromosomes Cancer, 49 (11), 1046-53
    DOI 10.1002/gcc.20813, PubMed 20725991
  10. Michelsen TM, Tonstad S, Pripp AH, Tropé CG, Dørum A (2010)
    Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
    Int J Gynecol Cancer, 20 (2), 233-9
    DOI 10.1111/igc.0b013e3181ca5ff4, PubMed 20169665
  11. Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL (2010)
    Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin
    Am J Pathol, 177 (3), 1087-94
    DOI 10.2353/ajpath.2010.100316, PubMed 20671266
  12. Pradhan M, Abeler VM, Davidson B, Kildal W, Nybøen A, Tropé CG, Risberg B, Danielsen HE (2010)
    DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
    Int J Gynecol Pathol, 29 (6), 572-8
    DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853
  13. Pradhan M, Risberg BA, Tropé CG, van de Rijn M, Gilks CB, Lee CH (2010)
    Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
    BMC Cancer, 10, 493
    DOI 10.1186/1471-2407-10-493, PubMed 20843305
  14. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010)
    Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
    J. Clin. Oncol., 28 (20), 3323-3329
    DOI 10.1200/JCO.2009.25.7519
  15. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM, MRC OV05, EORTC 55955 investigators (2010)
    Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
    Lancet, 376 (9747), 1155-63
    DOI 10.1016/S0140-6736(10)61268-8, PubMed 20888993
  16. Sert B (2010)
    Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes
    Int J Med Robot, 6 (2), 132-5
    DOI 10.1002/rcs.295, PubMed 20049750
  17. Sert MB (2010)
    Comparison between robot-assisted laparoscopic radical hysterectomy (RRH) and abdominal radical hysterectomy (ARH): a case control study from EIO/Milan
    Gynecol Oncol, 117 (2), 389; author reply 389-90
    DOI 10.1016/j.ygyno.2010.01.032, PubMed 20153028
  18. Tropé CG (2010)
    Management of cervical carcinoma stage IV: comment.
    CME Journal of Gynecologic Oncology, 15 (1), 69-71
    PublikaID 105
  19. Tropé CG, Kristensen GB (2010)
    The treatment of recurrent cervical cancer
    CME Journal of Gynecologic Oncology, 15 (1), 72-90
    PublikaID 106
  20. Tropé CG, Kristensen GB (2010)
    Surgery in treatment of recurrent cervical cancer
    CME Journal of Gynecologic Oncology, 15 (1), 33-39
    PublikaID 104
  21. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group (2010)
    Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
    N Engl J Med, 363 (10), 943-53
    DOI 10.1056/NEJMoa0908806, PubMed 20818904
  22. Wang Z, Trope CG, Flørenes VA, Suo Z, Nesland JM, Holm R (2010)
    Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
    BMC Cancer, 10, 233
    DOI 10.1186/1471-2407-10-233, PubMed 20500813
  23. Yuan Y, Leszczynska M, Konstantinovsky S, Tropé CG, Reich R, Davidson B (2010)
    Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
    Diagn Cytopathol, 39 (8), 562-6
    DOI 10.1002/dc.21424, PubMed 20730893

 
Page visits: 9591
Scroll to top